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Abstract
Background: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma
(RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. Ongoing
clinical trials are studying its activity in other malignancies, such as non-small-cell lung cancer (NSCLC). However, no
biological marker is known to define either the sensitivity or resistance to the drug.
Case presentation: Here we report a case of a patient with two synchronous tumors, HCC and NSCLC, with
metastases in the contralateral lung and bone. The patient was treated with gemcitabine as first line, with a resulting
progressive disease after two months, and then with sorafenib at standard dosage in the second line setting. After
6 months of treatment CT scan showed a partial response in the primary lesion of the lung, complete response of the
metastasis in the contralateral lung, and stability of HCC. The patient had progression in the lung, liver and bone after
13 months of therapy. A molecular characterization of NSCLC and HCC lesions was performed, revealing a BRAF exon
11 mutation (G469V) only in NSCLC. We hypothesize that the response observed in NSCLC lesions could be due to the
presence of BRAF mutation, and that this alteration could be responsible in determining sorafenib sensitivity.
Conclusions: Results observed in this case encourage further research on the activity of sorafenib in both HCC and
NSCLC, based on the presence of BRAF mutation. This could lead to a selection of HCC patients to be treated with this
drug, and could help identify a novel treatment strategy for BRAF-mutated NSCLC patients.
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Background
Sorafenib is a multi-targeted kinase inhibitor with proven
activity in renal cell carcinoma (RCC) and hepatocellular
carcinoma (HCC) [1, 2]. It was originally discovered as an
inhibitor of Raf-1 kinase, but was found to have an ex-
panded target profile with potent activity against other
kinases including BRAF, vascular endothelial growth fac-
tor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet de-
rived growth factor (PDGFR)-β, KIT, Flt-3, and RET. It
has a broad-spectrum efficacy in human tumor xenograft
models including NSCLC [3, 4].
NSCLC seemed an ideal disease in which to further
investigate sorafenib based on the frequency of RAS
mutations, particularly in adenocarcinomas [5–7]. Several
clinical trials have evaluated sorafenib in the treatment of
advanced NSCLC alone or in combination with chemo-
therapy or targeted agents, without reaching consistent re-
sults on efficacy [8–11]. Markers of sorafenib efficacy or
resistance have yet to be identified [12–15].
Case presentation
We present a case of a 74-year-old man smoker patient
with NSCLC with bone metastases (T2NXM1) and HCC
(BCLC stage C). The patient had a related liver cirrhosis
metabolic syndrome, good liver function (Child Pugh A5),
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and reported a diabetes mellitus type II in his past medical
history. In July 2014 for chest and abdominal pain he per-
formed a CT scan with evidence of lung and liver lesions,
and bone metastasis. Lung biopsy performed on primary
lung lesion showed pulmonary adenocarcinoma (TTF1
positive and p40 negative) (Fig. 1a-b) and liver biopsy
showed HCC (grade 2 Edmondson) (Fig. 1c-d). As the
patient was not in good clinical conditions due to grade
2 asthenia, we decided to start with gemcitabine in
monochemotherapy in August 2014. After 2 months of
chemotherapy a further CT scan showed a disease pro-
gression in both the lung and the liver. We decided to
initiate treatment with sorafenib with standard schedule
(400 mg bid continuously).
CT scan before therapy showed that the primary liver
lesion measured 97 mm × 98.3 mm (Fig. 2a). The pri-
mary lung lesion measured 40.9 mm × 29.3 mm (Fig. 2d)
and the metastasis in the contralateral lung measured
27 mm × 25 mm (Fig. 2d). After 20 days we decided to
reduce the dose of sorafenib to 400 mg per day for ad-
verse events (hypertension grade 2 and mucositis grade
3). This dose was maintained until progression, without
adverse events. CT scan after 2 months showed partial
response in both lung lesions and stable disease in the
liver and bone lesions. CT scan after 6 months of ther-
apy showed partial response of the primary lung lesion
and complete response of the lung metastasis (Fig. 2e).
HCC was stable (Fig. 2b). After 13 months of therapy
CT scan showed a disease progression in both the lung
and the liver (Fig. 2c-f). Due to poor performance status
of the patient we decided to treat patient with only best
supportive care.
The pulmonary lesion underwent routine diagnostic mo-
lecular characterization for EGFR, KRAS, NRAS, PIK3CA,
BRAF, ERBB2, ALK, DDR2, MAP2K1, RET mutations
using Myriapod Lung Status (MassARRAY Sequenom).
Results revealed an exon 11 point mutation on BRAF gene
(G469V).
The same analysis was performed on the liver lesion,
with no mutations in the different genes. Genomic DNA
extraction from both lesions was performed starting
from tumor sections composed of about 70 % of tumor
cells.
Taking into consideration our previous results obtained
in HCC patients, in which we have demonstrated that
specific polymorphisms of eNOS, VEGFA, VEGFC and
HIF-1alpha seem to correlate with response to sorafenib
[16–18], we performed the analysis of such polymorphisms
on our patient. Results showed an homozygous status for
eNOS VNTR (4bb) and HIF-1alpha rs12434438 GG. Both
of these polymorphisms were associated with a worse
prognosis in our previous studies [16–18].
The molecular determinations performed on the liver
lesion (not part of routine molecular diagnostics) and the
polymorphism analyses, both part of an ongoing research
protocol on liver cancer approved by our Local Ethics
Committee, were carried out after obtaining written
consent from the patient.
Fig. 1 Lung: high power view of aggregate of primary lung adenocarcinoma cells a, with diffuse and intense nuclear staining for Thyroid
transcription factor-1 (TTF-1). b. Liver: high power view of HCC, c, with a distinct granular cytoplasmic staining for HepPar-1, d
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Conclusions
In this case report we showed that BRAF-mutated tu-
mors could be responsive to sorafenib. Results of recent
studies have shown an activity of anti-BRAF agents, such
as vemurafenib and dabrafenib, in BRAF V600E-mutated
NSCLC patients [19, 20]. In a retrospective study per-
formed on BRAF mutated NSCLC patients receiving
anti-BRAF treatment outside clinical studies, one patient
was treated with sorafenib showing a partial response
[21]. Very few data are present in the literature on the
role of BRAF non-V600E mutations in determining the
type of response to anti-BRAF agents in NSCLC. A case
report of a patient with BRAF G469L demonstrated ab-
sence of response to vemurafenib [22]. Conversely, an-
other case report of a patient with lung adenocarcinoma
harboring BRAF G469R mutation, showed a strong and
rapid response to sorafenib [5] for up to 6 months.
Moreover, a recent case report demonstrated a strong
and durable response to sorafenib in a patient with lung
adenocarcinoma carrying an ARAF (p. S214C) mutation
[23], suggesting the potential of this drug in treating pa-
tients with alterations in this pathway. No clinical studies
have evaluated the role of sorafenib in BRAF mutated
NSCLC patients, and clinical trials on sorafenib in
unselected patients with advanced NSCLC have demon-
strated modest activity, with no survival advantage [7, 10].
A phase II study evaluated the activity of sorafenib in
an unselected NSCLC case series. In this study, per-
formed on 34 patients, 2 partial responses and 20 stable
diseases were observed, without correlation with nei-
ther KRAS nor EGFR statuses. However, BRAF status
was not determined [24].
We report a case showing efficacy of sorafenib in one
NSCLC patient carrying an exon 11 G469V BRAF muta-
tion. The patient, treated with sorafenib for synchronous
HCC, showed a good response in lung lesions, carrying
the BRAF mutation, whereas no response was observed
in the hepatic lesion, which was BRAF wt. Conflicting
results are found in the literature on the frequency of
BRAF mutation in HCC, as about 20 % of HCC mutated
in one Italian study [25], whereas no or a very low muta-
tion rate was observed in other studies [26, 27]. How-
ever, no results are reported on the correlation between
BRAF mutation and sorafenib response in this pathology.
Results of this case report seem to suggest that sorafenib
activity could be more evident in lesions carrying a BRAF
mutation (lung lesions in this case), with respect to the
BRAF wt lesion (hepatic lesion). Although no correlation
Fig. 2 CT scan confirmed the presence of liver, a and lung lesions, d. CT re-evaluation after 6 months showed stability of HCC, b, a partial response in
the right lobe of the lung and a complete response in the left lobe of the lung, e. Disease progression in the lung and liver, c-f
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has been observed between sorafenib and KRAS mutation,
the association with BRAF mutation remains to be estab-
lished. As biochemical assays, performed to demonstrate
the activity of the drug on the different components of
RAF/MEK/ERK pathway, showed that the higher activity
of sorafenib is evident against CRAF and BRAF (both wt
and mutant) proteins [28], we hypothesized that sorafenib
could be effective in BRAF mutated cells, where the RAF
pathway is constitutively activated.
With regard to polymorphisms analyses, the results
indicated a patient genotype correlated to a worse prog-
nosis, as we previously found [16–18], in accordance
with the absence of response observed in this patient’s
HCC lesion.
In conclusion, our results suggest that sorafenib could
be effective in BRAF-mutated tumors. Considering that
sorafenib is able to induce clinical response in about
30 % of HCC patients, it could be worth verifying the
real frequency of BRAF mutations in this type of cancer,
and whether a higher frequency of mutation is related to
sorafenib response. In addition, clinical trials that evalu-
ate the efficacy of sorafenib in NSCLC patients carrying
BRAF mutations would be highly beneficial.
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